ArticleTheranostics2020
Amelioration of ulcerative colitis
Article in Theranostics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 151 citations in OpenAlex.
- Immune cell-derived membrane nanovesicles: A promethean fire for autoimmune disease therapy through immune cell mimicry.Bioactive materials · 2026Review
- Thiol-mediated ROS-responsive hydrogel with arginine-driven NO cascade for colitis treatment.Materials today. Bio · 2026Article
- Integrated Multi-Omics Analysis of Antarctic Krill Oil in Alleviating DSS-Induced Colitis and Modulating Gut Microbiota in Mice.Marine drugs · 2026Article
- Nanomedicine targeting neuroinflammatory pathways in Alzheimer's disease: a new frontier in inflammopharmacology.Inflammopharmacology · 2026Review
- Biomaterial-guided macrophage modulation: Therapeutic engineering of immune microenvironments.Trends in immunology · 2026Review
- Advances in nano-TCM for Alzheimer's disease: lipid-based carriers integrated with innovative delivery strategies.Journal of nanobiotechnology · 2026Review
- Advances of Cell Membrane-Coated Nanotechnology and Membrane Vesicles in Intestinal Targeted Drug Delivery Systems.Pharmaceutics · 2026Review
- Novel perspective on immune cell regulation in gastrointestinal inflammation: the role of extracellular vesicles and therapeutic prospects.Experimental biology and medicine (Maywood, N.J.) · 2026Review
- Nanoparticle-Mediated PPAR Modulation of Macrophage Polarization in Radiation Enteritis: A Narrative Review.Drug design, development and therapy · 2026Review
- Sunitinib induces macrophage dysfunction and impaired tissue regeneration through suppression of PPARγ.Frontiers in immunology · 2026Article
- HPDA-based tubule-targeting nanoplatform alleviates oxidative stress and ferroptosis for the reversal of renal interstitial fibrosis.Journal of nanobiotechnology · 2025Article
- Biomimetic nanocarriers for the therapy and management of intestinal inflammations.International journal of pharmaceutics: X · 2025Review
- Polydopamine Nanodots Ameliorate Inflammatory Bowel Disease by Restoring Redox Homeostasis and Intestinal Microenvironment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Micro/nano motors treating of digestive system diseases.Journal of nanobiotechnology · 2025Review
- Safflower Polysaccharides Alleviate TNBS-Induced Colitis by Modulating Gut Immunity.Foods (Basel, Switzerland) · 2025Article
- Integrated serum pharmacochemistry and network pharmacology to reveal the kernel material basis and underlying mechanisms of the fuzi-lizhong pill for ulcerative colitis.Journal of traditional and complementary medicine · 2025Article
- Applications of Cyclodextrin-Based Drug Delivery Systems in Inflammation-Related Diseases.Pharmaceutics · 2025Review
- Classification of Nanomaterial Drug Delivery Systems for Inflammatory Bowel Disease.International journal of nanomedicine · 2025Review
- Research advances in nanomaterials with aromatic functional groups for the treatment of inflammatory bowel disease.Frontiers in bioengineering and biotechnology · 2025Review
- Macrophages: emerging targets for ulcerative colitis.Frontiers in immunology · 2025Review
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ulcerative colitis (UC) is featured with relapsing inflammation in the colon, where macrophages are recruited and polarized locally into M1 type to drive further inflammation. Pharmacotherapy of UC has exhibited limited efficacy, mostly due to the poor specificity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.